Liraglutide effective in reducing weight in obese COPD
Liraglutide is beneficial in reducing weight as wel as increasing forced vital capacity (FVC) in obese patients with COPD. The drug, indicted for treatment of type 2 diabetes mellitus uncontrolled by diet and exercise, also increases carbon monoxide diffusion capacity and improving COPD Assessment Test (CAT) scores in obese patients, suggested a the findings of a new controlled, double-blind trial. The study published in the International Journal of Chronic Obstructive Pulmonary Disease, the researchers wrote that they treated 40 patients with liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for weight loss and for the treatment of type-2 diabetes. The team observed that FVC increased by 7.69 percent (P =.018), and FVC best measure (FVCbest) went up by 0.33 L in the liraglutide group, compared with levels in the placebo group.